The initial public offering (IPO) of Corona Remedies Ltd, a pharmaceutical company operating across multiple therapeutic categories, opened for public subscription on Monday, December 8, 2025. On Day 1 of the bidding process, the IPO witnessed a subscription of 30% so far, reflecting steady investor interest as the issue entered its first trading session.
Corona Remedies, which develops, manufactures and markets pharmaceutical products in women’s healthcare, cardiology, pain management, urology, and several other segments, has launched its IPO at a time when grey market activity and investor participation remain sharply focused on the company’s fundamentals and pricing.
IPO Dates, Price Band & Size
The IPO opened on December 8 and will close on Wednesday, December 10. The company’s share allotment is likely to be finalised on December 11, and the listing is scheduled for December 15 on both the BSE and NSE.
Corona Remedies has fixed its IPO price band at ₹1,008 to ₹1,062 per share. At the upper end of this band, the company aims to raise ₹655.37 crore through a book-building issue. The entire IPO is an offer for sale (OFS) comprising 61.71 lakh equity shares, meaning no fresh shares are being issued and all proceeds will go to selling shareholders.
Lot Size & Minimum Investment
The lot size for the IPO is 14 shares, making the minimum retail investment ₹14,868 at the lower end of the price band. This positions Corona Remedies within the typical investment threshold seen across mid-sized pharma IPOs, keeping the retail entry point accessible to a majority of individual bidders.
JM Financial Ltd is serving as the book-running lead manager for the issue, while Bigshare Services Pvt. Ltd is the registrar handling allotment and investor communication.
Grey Market Premium (GMP) Trends
One of the most critical indicators for IPO sentiment — the grey market premium (GMP) — has shown strong traction.
According to platforms tracking the unlisted market, the Corona Remedies IPO GMP today stands at ₹290 per share. This means the company’s shares are trading ₹290 higher than the issue price in the unofficial grey market.
At this premium, Corona Remedies shares are being traded at ₹1,352 apiece in the grey market. This reflects a 27.31% premium over the IPO’s upper price band of ₹1,062 per share — indicating expectations of a robust listing, provided the sentiment sustains throughout the subscription period.
GMP trends are watched closely by market participants, although they are not an official indicator. Still, a premium of this scale points towards enthusiastic sentiment around the offering on Day 1.
Subscription Status on Day 1
On the opening day of bidding, the issue was subscribed to nearly 30%, showing a moderate yet steady interest from early participants. With two days remaining before the closing date, investor demand from retail, non-institutional and QIB categories will determine how the IPO shapes up by the final day.
The subscription numbers will evolve throughout the day as more bids come in, and updated figures are expected to reflect participation trends across segments.
Company Overview (Only What’s Provided)
Corona Remedies is a pharmaceutical company working across multiple therapeutic areas, including:
Women’s healthcare
Cardiology
Pain management
Urology
Other therapeutic segments
The company develops, manufactures and markets its product range, positioning it across key high-demand segments within the pharma space.
No additional financials, revenue details, or profit metrics were provided in the source, and therefore are not included here.
Key Highlights of Corona Remedies IPO
IPO opened December 8, closes December 10
Price band: ₹1,008–₹1,062
Issue size: ₹655.37 crore
Offer type: 100% Offer for Sale (61.71 lakh shares)
Lot size: 14 shares
Minimum retail investment: ₹14,868
Listing date: December 15
Exchanges: NSE & BSE
Lead manager: JM Financial
Registrar: Bigshare Services
GMP today: ₹290 per share
Implied grey market price: ₹1,352
Premium over issue price: 27.31%
Subscription so far: ~30% on Day 1
Market Sentiment & What to Watch Next
With the grey market premium holding strong at 27% and subscription picking up pace during early hours, market watchers will track:
Whether GMP stays stable over the next two days
Retail and NII (HNI) demand on Day 2 and Day 3
QIB participation on the final day
Any major shifts in subscription patterns
The company’s listing performance on December 15 will ultimately reflect broader investor confidence and market sentiment surrounding mid-sized pharma IPOs.
Click here to explore:
Corona Remedies IPO
